Is Crawford & Co. overvalued or undervalued?

As of 19 May 2025, the valuation grade for Crawford & Co. has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 18, an EV to EBITDA of 4.20, and a PEG ratio of 0.46, which suggests that the stock is reasonably priced relative to its growth potential.
In comparison to peers, Crawford & Co. has a P/E ratio of 16.08, which is more attractive than Hippo Holdings, Inc. at -13.62, and is competitive against GoHealth, Inc. with a P/E of 4.94. Additionally, Crawford's ROCE stands at an impressive 74.93%, reflecting strong operational efficiency. Notably, the company's stock has outperformed the S&P 500 over the past year, returning 21.05% compared to the index's 10.26%, reinforcing its valuation outlook.